p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.

The p53 protein plays a key role in securing the apoptotic response of chronic lymphocytic leukemia (CLL) cells to genotoxic agents. Transcriptional induction of proapoptotic proteins including Puma are thought to mediate p53-dependent apoptosis. In contrast, recent studies have identified a novel nontranscriptional mechanism, involving direct binding of p53 to antiapoptotic proteins including Bcl-2 at the mitochondrial surface. Here we show that the major fraction of p53 induced in CLL cells by chlorambucil, fludarabine, or nutlin 3a was stably associated with mitochondria, where it binds to Bcl-2. The Puma protein, which was constitutively expressed in a p53-independent manner, was modestly up-regulated following p53 induction. Pifithrin alpha, an inhibitor of p53-mediated transcription, blocked the up-regulation of Puma and also of p21(CIP1). Surprisingly, pifithrin alpha dramatically augmented apoptosis induction by p53-elevating agents and also accelerated the proapoptotic conformation change of the Bax protein. These data suggest that direct interaction of p53 with mitochondrial antiapoptotic proteins including Bcl-2 is the major route for apoptosis induction in CLL cells and that p53's transcriptional targets include proteins that impede this nontranscriptional pathway. Therefore, strategies that block up-regulation of p53-mediated transcription may be of value in enhancing apoptosis induction of CLL cells by p53-elevating drugs.

[1]  James M. Roberts,et al.  CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .

[2]  Earl F. Glynn,et al.  Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function , 2008, Nature Medicine.

[3]  N. Plesnila,et al.  Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-κB transcriptional activity , 2007, Cell Death and Differentiation.

[4]  A. Pettitt,et al.  The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia , 2007, Leukemia.

[5]  K. Vousden,et al.  p53: new roles in metabolism. , 2007, Trends in cell biology.

[6]  Augusto Silva,et al.  Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation , 2007, Apoptosis.

[7]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[8]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[9]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[10]  K. Vousden.  Outcomes of p53 activation - spoilt for choice , 2006, Journal of Cell Science.

[11]  T. Yamagata,et al.  TEL/ETV6 induces apoptosis in 32D cells through p53-dependent pathways. , 2006, Biochemical and biophysical research communications.

[12]  Marina Konopleva,et al.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.

[13]  L. Zhang,et al.  Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis , 2006, Oncogene.

[14]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[15]  R. Fanin,et al.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .

[16]  S. Lowe,et al.  Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. , 2006, Experimental hematology.

[17]  Horst Kessler,et al.  WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization* , 2006, Journal of Biological Chemistry.

[18]  J. Charlot,et al.  Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-α on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells , 2006, Apoptosis.

[19]  M. Christmann,et al.  Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. , 2005, Cancer research.

[20]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[21]  Sudhir V. Shah,et al.  p53-dependent Caspase-2 Activation in Mitochondrial Release of Apoptosis-inducing Factor and Its Role in Renal Tubular Epithelial Cell Injury* , 2005, Journal of Biological Chemistry.

[22]  T. Kipps,et al.  Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. , 2005, Blood.

[23]  A. Gudkov,et al.  Prospective therapeutic applications of p53 inhibitors. , 2005, Biochemical and biophysical research communications.

[24]  L. Greene,et al.  Puma and p53 Play Required Roles in Death Evoked in a Cellular Model of Parkinson Disease , 2005, Neurochemical Research.

[25]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[26]  G. Klein,et al.  Wild-type p53 activates SAP expression in lymphoid cells , 2004, Oncogene.

[27]  R. Hamdy,et al.  Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice , 2004 .

[28]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[29]  A. Gunasekera,et al.  Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR , 2004, FEBS letters.

[30]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[31]  A. Newland,et al.  Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. , 2003, Biochemical and biophysical research communications.

[32]  C. Culmsee,et al.  Reciprocal Inhibition of p53 and Nuclear Factor-κB Transcriptional Activities Determines Cell Survival or Death in Neurons , 2003, The Journal of Neuroscience.

[33]  Dylan T. Jones,et al.  Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. , 2003, Blood.

[34]  K. Roemer,et al.  Inhibition of p53 protects liver tissue against endotoxin‐induced apoptotic and necrotic cell death , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  T. Burns,et al.  Microarray Analysis of p53 Target Gene Expression Patterns in the Spleen and Thymus in Response to Ionizing Radiation , 2003, Cancer biology & therapy.

[36]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[37]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[38]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[39]  A. Garden,et al.  A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  K. Ganeshaguru,et al.  Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. , 2001, Blood.

[41]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.

[42]  J. Vilpo,et al.  Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles and doses. , 2000, Pharmacology & toxicology.

[43]  M V Chernov,et al.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.

[44]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[45]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[46]  H. Döhner,et al.  Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids , 2007, Leukemia.

[47]  M. Konopleva,et al.  may overcome Atm-mediated resistance to fludarabine in chronic transcription-dependent and transcription-independent mechanisms Mdm 2 inhibitor Nutlin-3 a induces p 53-mediated apoptosis , 2006 .

[48]  M. Konopleva,et al.  Mdm 2 inhibitor Nutlin-3 a induces p 53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to Fludarabine in chronic lymphocytic leukemia , 2006 .

[49]  T. Stankovic,et al.  Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. , 2004, Blood.

[50]  J. Trapani,et al.  Assaying cytochrome C translocation during apoptosis. , 2004, Methods in molecular biology.

[51]  M. Ramsby,et al.  Differential detergent fractionation of eukaryotic cells. Analysis by two-dimensional gel electrophoresis. , 1999, Methods in molecular biology.

[52]  A. G. Bosanquet,et al.  Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. , 1996, Blood.

[53]  G. L. Peterson.  Determination of total protein. , 1983, Methods in enzymology.

[54]  G. L. Peterson.  [12] Determination of total protein , 1983 .